# Banner Plans & Networks Behavioral Health Toolkit

# Contents

Introduction Letter
Best Practices
Best Practices for Adults with Depression5
Best Practices for Adults with Anxiety7
Best Practices for Older Adults with Depression9
Best Practice for Children or Adolescents with Depression11
Best Practice for Children or Adolescents with Anxiety13
Tip Sheets
Depression & Anxiety Screening Tips16
Documenting Follow-ups16
PHQ-9 Interpretation, Treatment & Determining Remission17
Behavioral Health Coding & Documentation18
Provider & Patient Resources
*Crisis Resources
What is a Behavioral Health Emergency?21
National 24-Hour Crisis Hotlines21
Suicide & Crisis Hotlines by County21
Warm Lines by County21
Banner - University Health Plans – Behavioral Health Care Management & Provider Referral22
Banner - Aetna Mental Wellbeing Resource Center24
Humana Behavioral Health Consult Team25
Arizona Perinatal Psychiatry Consult Line26
Banner Health Network Pyx Health Program27
Screening Tools
PHQ – 2 Short Depression Screening Tool29
PHQ – 9 Depression Screening
GAD – 7 Anxiety Screening
Geriatric Depression Scale (GDS)- Short Form32
Edinburgh Postnatal Depression Scale (EPDS)34
PHQ – A (PHQ-9 Modified for Adolescents)
SMFQ – Short Mood & Feelings Questionnaire37
Tool Kit Survey
References

# Introduction Letter

1/15/2024

Dear Providers:

Banner Plans & Networks continue to make strides in providing clinically relevant opportunities that impact the quality of care for our members. The Banner Plans and Networks Behavioral Health Clinical Strategy Committee has devised best practices and a toolkit, geared toward Primary Care Physicians to improve outcomes for patients with behavioral health issues.

Depression contributes to most adult primary care visits, often in the form of somatic symptoms, and is diagnosed and treated most frequently by PCPs<sup>1,2</sup>. However, up to half of all cases of depression remain undetected, and even those patients who are appropriately diagnosed frequently do not receive treatment in accordance with recommended guidelines<sup>3</sup>. Depression is a leading cause of disability. It interferes with treatment adherence and exacerbates the course of chronic diseases such as cardiovascular disease, diabetes, obesity, and immune disorders, resulting in poorer outcomes<sup>4</sup>. Depression frequently leads to physical inactivity, sleep disturbances, smoking, excessive alcohol consumption or other substance use, and poor nutrition, further compromising the physical health of patients.

# We encourage you to screen for depression using standardized tools such as the PHQ-2 and/or PHQ-9 at least annually. Screening for anxiety is recommended as well, using the GAD-7.

The resources we've put together for you are based on Evidence Based Practice and the latest clinical guidelines.

#### **Toolkit Items:**

- Best Practice for Adult Depression
- Best Practice for Adult Anxiety
- Best Practice for Older Adult Depression
- Best Practice for Pediatric Depression
- Best Practice for Pediatric Anxiety
- Screening Tools
- Behavioral Health Coding Guidelines
- Behavioral Health Billing Guidelines
- Resources for Providers & Patients

We hope these resources assist you in your practice. Thank you for your ongoing work to help Banner Plans and Networks make health care easier, so life can be better.

Sincerely,

Dr. Vicki Knight

Medical Director Chairperson of Behavioral Health Clinical Strategy Committee Banner Plans & Networks

# **Best Practices**

### Best Practices for Adults with Depression

#### Why Screen and Treat Adults with Depression?

Depression contributes to most adult primary care visits, often in the form of somatic symptoms, and is diagnosed and treated most frequently by PCPs<sup>1,2</sup>. However, up to half of all cases of depression remain undetected, and even those patients who are appropriately diagnosed frequently do not receive treatment in accordance with recommended guidelines<sup>3</sup>. Depression is a leading cause of disability. It interferes with treatment adherence and exacerbates the course of chronic diseases such as cardiovascular disease, diabetes, obesity, and immune disorders, resulting in poorer outcomes<sup>4</sup>. Depression frequently leads to physical inactivity, sleep disturbances, smoking, excessive alcohol consumption or other substance use, and poor nutrition, further compromising the physical health of patients.

#### **Risk Factors and Screening to Detect Depression in Adults:**

Those with significant risks factors should be screened using appropriate tools below:

Adults	Geriatric	Pregnant & Postpartum
PHQ-9	Geriatric Depression Scale	Edinburgh Postpartum Depression Scale
Female gender	Disability	Poor self-esteem
At risk age range (18-29)	Poor physical health status	Child care stressors
Undereducated	Complicated grief	Prenatal anxiety
Previously married	Chronic sleep disturbances	Life stress
Unemployed	Loneliness	Descreased social support
Chronic Illnesses	Hx of depression	Single/unpartnered relationship status
Hx of Depression or Substance Use		Difficult infant temperament
Family Hx of depression		Hx of postpartum depression or depression
Family Hx of psychiatric disorders		Lower Socioeconomic status
		Unintended pregnancy

#### All Adults ages 18 and over should be screened annually using the PHQ-2 or PHQ-9

#### **How Often to Screen?**

- Annually if no significant risk factors or previous positive screening
- Quarterly after initial positive screening
- Following reports of depressive symptoms, change in risk factors or significant life events
- In accordance with clinical judgement

#### **Evaluation and Diagnosis of Depressive Disorders:**

#### DSM-5-TR Criteria for Major Depressive Disorder (MDD)

 Five or more of the following symptoms during the same 2-week period, occurring most of the days, nearly every day.

Criteria for Major Depressive Disorder (MDD)		
Depressed Mood (Subjective or Observed)	Psychomotor Agitation or Retardation	
Loss of Interest/Pleasure in Activities	Fatigue or Loss of Energy	
Significant Unintentional Weight Loss or Gain	Feelings of Worthlessness or Excessive Guilt	
Decrease or Increase in Appetite	Decreased Concentration	
Insomnia or Hypersomnia	Recurrent Thoughts of Death/Suicide	

These guidelines serve to assist in the management, documentation, and coding of clinical diagnoses. The intent of this document is to supplement, but not replace, the provider's clinical judgement.

Banner Plans & Networks Confidential Information

# **Best Practices**

#### DSM-5-TR Criteria for Major Depressive Disorder (MDD) – Continued

- Symptoms must represent a change from a previous level of functioning.
- Symptoms must cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
- Episode must not be attributable to the physiological effects of a substance or another medical condition.
- Episode is not better explained by a schizophrenia spectrum diagnosis.
- No history of manic or hypomanic episodes.

#### **Depression Treatment Guidelines:**

Nonpharmaceutical Treatment Interventions for Depression			
Psychotherapy		Other	
<ul> <li>Behavioral Therapy</li> <li>Cognitive Behavioral Therapy (CBT)</li> <li>Interpersonal Therapy</li> <li>Psychodynamic Therapy</li> <li>Supportive Therapy</li> <li>Mindfulness</li> </ul>		ivulsive Therapy (EC ial Magnetic Stimula	,
<b>Pharmaceutical Treatment for Depressi</b>	on	Starting Dose	Usual Dose
SSRI's (Selective Serotonin Reuptake Inhibitors) Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Paroxetine (Paxil) Paroxetine, extended release (Paxil CR) Sertraline (Zoloft)		20 mg 10 mg 20 mg 12.5 mg 50 mg	20-60 mg 10-20 mg 20-60 mg 20-60 mg 25-75 mg 50-200 mg
DNRI's (Dopamine Norepinephrine Reuptake Inhibit Bupropion, immediate release (Wellbutrin) Bupropion, sustained release (Wellbutrin SR) Bupropion, extended release (Wellbutrin XL)	ors)	150 mg 150 mg 150 mg	300-450 mg 300-450 mg 300-450 mg
SNRI's (Serotonin Norepinephrine Reuptake Inhibito Venlafaxine, immediate release (Effexor) Venlafaxine, extended release (Effexor XR) Desvenlfaxine (Pristiq) Duloxetine (Cymbalta)	ors)	37.5 mg 37.5 mg 50 mg 60 mg	75-375 mg 75-375 mg 50 mg 120 mg
Norepinephrine-Serotonin Modulator Mirtazepine (Remeron)		15 mg	15-45 mg
TCA's (Tricyclic Antidepressants) Amitriptyline (Elavil) Doxepin (Sinequan, Silenor) Imipramine (Tofranil) Nortriptyline (Pamelor)		25-50 mg 25-50 mg 25-50 mg 25 mg	100-300 mg 100-300 mg 100-300 mg 50-200 mg
MAOI's (Monoamine Oxidase Inhibitors) Phenelzine (Nardil) Tranylcypromine (Parnate) Isocarboxazid (Marplan)		15 mg 10 mg 10-20 mg	45-90 mg 30-60 mg 30-60 mg

#### **Indications for Referral to Psychiatric Providers:**

Indications for Specialty Referral		
Patient Preference for Therapy Before Medication	Lack of Response to Trials of Multiple Medications	
Suicidality or History of Suicide Attempts	Concerns for Mania or Psychotic Features	
Complex Clinical Presentation	Diagnostic Uncertainty	
Chronic and Recurrent Depression	Co-occurring Mental Health & Substance Use	
History of Significant Trauma	Co-occurring Mental Health & Personality Disorders	

Banner Plans & Networks Confidential Information

### Best Practices for Adults with Anxiety

#### Why Screen and Treat Adults with Anxiety?

Anxiety is the most common psychiatric disorder in the United States, affecting up to one-third of individuals at some time in their lives. Women more commonly are affected than men. Although anxiety is a frequent cause of significant functional impairment in adults, only about 10% of patients with anxiety disorders receive treatment within one year of onset, and fewer than 40% receive any treatment at all for the disorder<sup>6</sup>. Patients are most likely to present initially to a primary care provider with a variety of somatic complaints (such as heart palpitations, an increased heart rate, shortness of breath, chest tightness, feelings of fatigue, headache, GI disturbances, sensations of numbness or tingling, dizziness, difficulty sleeping or muscle weakness), rather than explicit emotional or behavioral health concerns. Up to 60-75% of individuals with depression have a comorbid anxiety disorder.

#### **Common Types of Anxiety Disorders:**

**Generalized Anxiety Disorder:** An excessive, persistent, and unrealistic worry about everyday life events, often accompanied by physical symptoms, that produces a constant feeling of being overwhelmed. **Social Anxiety Disorder:** Fear of situations in which an individual may be scrutinized, evaluated, or judged by others.

**Panic Disorder:** Characterized by sudden episodes of intense fear that trigger severe physical reactions when there is no real danger or apparent cause.

**Post-Traumatic Stress Disorder:** A condition in which a traumatic event is persistently re-experienced in the form of intrusive recollections, dreams or dissociative flashback episodes.

**Obsessive-Compulsive Disorder:** Characterized by repeated, persistent, and unwanted thoughts, urges or images that are intrusive and cause distress, accompanied by repetitive, ritualistic behaviors that follow specific rules and patterns to help diminish the feelings of distress.

**Phobias:** Uncontrollable, irrational, and persistent fears of specific objects, situations, or activities.

#### **Risk Factors and Screening to Detect Anxiety in Adults:**

Those with significant risks factors should be screened using appropriate tools:

Risk Factors		
Female gender	Early parental loss	
Family history of anxiety/depression	Childhood trauma or sexual abuse	
History of self-harm by age 16	Substance Use Disorder before age 21	
Stressful environment (home, work, school)	Limited education	
Low self esteem	Loneliness	
Chronic medical conditions	Socioeconomic & cultural factors	
Personality traits such as: introversion, overthinking, perfectionism, resistance to change, empathy		

#### **How Often to Screen?**

- Annually if no significant risk factors or previous positive screening
- Quarterly after initial positive screening
- Following reports of anxiety symptoms, change in risk or significant life events
- In accordance with clinical judgement

#### **Tools for Screening:**

Generalized Anxiety Disorder 2-item or 7-item - GAD 2 or GAD-7

These guidelines serve to assist in the management, documentation, and coding of clinical diagnoses. The intent of this document is to supplement, but not replace, the provider's clinical judgement.

#### **Evaluation and Diagnosis of Anxiety:**

#### DSM-5-TR Criteria for Generalized Anxiety Disorder (GAD)

Excessive anxiety and worry about numerous events or activities that are difficult to control and occur more days than not for at least 6 months, accompanied by at least 3 of the 6 symptoms:

Criteria for Generalized Anxiety Disorder		
Restlessness Being easily fatigued		
Difficulty concentrating	Irritability	
Muscle tension	Sleep disturbances	

• Symptoms must cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.

• The patient's clinical presentation is not better explained by another mental health disorder, the physiological effects of a substance, or another medical condition.

#### **Anxiety Treatment Guidelines:**

Nonpharmaceutical Treatment Interventions for Anxiety				
• Education, reso	urces & monitoring • Relaxation therapy & techniques		les	
Cognitive Behav	vioral Therapy (CBT)			
<ul> <li>Self-help &amp; psyc</li> </ul>	choeducational groups			
	cal Treatment for Anxiety		Starting Dose	Usual Dose
SSRI's (Selective	Serotonin Reuptake Inhibitors)			
	Citalopram (Celexa)		20 mg	20-60 mg
	Escitalopram (Lexapro)		10 mg	10-20 mg
	Fluoxetine (Prozac)		20 mg	20-60 mg
	Paroxetine (Paxil)	<b>ח</b>	20 mg	20-60 mg
	Paroxetine, extended release (Paxil C	K)	12.5 mg	25-75 mg
	Sertraline (Zoloft)	· · · · ·	50 mg	50-200 mg
SNRI's (Serotonir	Norepinephrine Reuptake Inhibito		27 E m a	7E 27E m a
	Venlafaxine, immediate release (Effex Venlafaxine, extended release (Effex		37.5 mg 37.5 mg	75-375 mg 75-375 mg
	Desvenlfaxine (Pristiq)	n AR)	50 mg	50 mg
	Duloxetine (Cymbalta)		60 mg	120 mg
Azapirones	Buspirone (Buspar)		7.5 mg BID	20-30 mg QD
Azapirones	buspirone (buspar)		7.5 mg DID	Daily Max 60 mg
Antihistamines	Hydroxyzine (Vistaril, Atarax) 50-100 mg up to 4 times daily			
	Diphenhydramine (Benadryl)		25-50 mg up to 4-6 times daily	
Gabapentinoids	Pregabalin (Lyrica)		50 mg TID or	450 mg daily
			75 mg BID	Daily Max 600 mg
	Gabapentin (Neurontin)		300 mg QD	600-1800 mg
				Daily Max 3600 mg
Benzodiazepines	enzodiazepines *Short term use only (2 weeks), avoid in patients with history of substance use disorders,			
	scheduled doses (not PRN), use agents with longer half-lives)			
Long Acting -	Clonazepam (Klonopin)		0.5-1 mg BID or TID	Daily Max 20 mg
	Diazepam (Valium)		2-10 mg BID to QID	Daily Max 40 mg
Short Acting -	Lorazepam (Ativan)		0.5-1 mg TID or QID	Daily Max 10 mg
e.i.ere / ieting	,		0.25-0.5 mg BID/TID	Daily Max 4 mg
	Alprazolam (Xanax)			Daily Max 4 Hig

#### **Indications for Referral to Psychiatric Providers:**

Indications for Specialty Referral		
Patient Preference for Therapy Before Medication	Lack of Response to Trials of Multiple Medications	
Severe impairment in daily functioning	Co-occurring Mental Health & Substance Use	
Complex Clinical Presentation	Diagnostic Uncertainty	

Banner Plans & Networks Confidential Information

### Best Practices for Older Adults with Depression

#### Why Screen and Treat Older Adults with Depression?

Up to 80% of older adults who are treated for mental health disorders receive care for these conditions from primary care providers<sup>5</sup>. Unfortunately, depression in the elderly is often considered a normal part of the aging process. Depressive disorders therefore are under-recognized, underdiagnosed, and under-treated in this population. Current evidence indicates that older adults are at increased risk for experiencing depression. However, elderly patients with depression tend to report more somatic and cognitive symptoms than affective symptoms. In addition, features of medical comorbidities frequently are present that may complicate the patient's diagnosis and presentation, such as fatigue, weight loss, and insomnia. Depression in older adults is known to be associated with significant negative consequences, including poor quality of life, difficulties with activities of daily living, physical comorbidities, premature mortality, and cognitive impairment. Some of these symptoms are not included in the DSM 5-TR criteria for Major Depressive Disorder but may be categorized as Other Specified Depressive Disorder. Depression is a significant predictor of suicide in the elderly, particularly among white males aged 85 and older, who have a suicide rate that is six times higher than the general population<sup>7</sup>.

#### **Risk Factors and Screening to Detect Depression in Older Adults:**

Risk Factors for Depression in Older Adults		
Chronic Medical Conditions	Chronic Stress	
Social isolation and Loneliness	Cognitive Impairment	
Bereavement	Functional Limitations/Difficulty Performing ADLs	
Sleep Problems	Prior History or Family History of Depression	
Lack of Exercise or Physical Activity	Substance Use	

Those with significant risks factors should be screened using tools below:

Screening Tools		
PHQ-2	PHQ-9	Geriatric Depression Scale

#### How Often to Screen?

- Annually if no significant risk factors or previous positive screening
- Quarterly after initial positive screening
- Following reports of depressive symptoms, change in risk factors or significant life events
- In accordance with clinical judgement

#### **Evaluation and Diagnosis of Depressive Disorders:**

Diagnostic criteria for depression is the same in adults of any age. However, symptoms more commonly present in older adults include:

Diagnostic Criteria for Depression		
Fatigue/feeling tired/lack of energy	Lack of pleasure/enjoyment in usual activities	
Difficulty sleeping	Psychomotor retardation	
Irritability	Change in weight or appetite	
Confusion	Frequent/persistent aches and pains	
Difficulty paying attention	Suicidal ideation	
Feelings of hopelessness, worthlessness, and guilt		

#### **Physiological Factors, Risks, and Medication Considerations:**

Physiological Factors/Conditions Associated with Depression in Older Adults:		
Inflammation/autoimmune disorders	<ul> <li>Cancer/malignancy (particularly pancreatic)</li> </ul>	
Cardiovascular/Cerebrovascular disease	Viral infections	
Neurodegeneration	Metabolic disorders/nutritional deficiencies	
Endocrine disorders		
Risks Associated with Antidepressant Use in Older Adults:		
• Falls	Anticholinergic effects	
Osteoporosis/fractures	Extrapyramidal symptoms	
Orthostatic hypotension	<ul> <li>Medication interactions/polypharmacy</li> </ul>	
Sedation	Cardiac effects	
Medication Considerations:		
Lower initial doses	TCAs generally not recommended	
• SSRIs preferred over SNRIs as first line treatment	<ul> <li>Consider medications with prior response</li> </ul>	

#### **Indications for Referral to Psychiatric Providers:**

Indications for Specialty Referral		
Suicidal ideation	Lack of Response	
Psychosis	Diagnostic complexity/uncertainty	
Unable to tolerate initial medications	Possible need for ECT to induce rapid response	

These guidelines serve to assist in the management, documentation, and coding of clinical diagnoses. The intent of this document is to supplement, but not replace, the provider's clinical judgement.

### Best Practice for Children or Adolescents with Depression

#### Why Screen and Treat Children or Adolescents with Depression?

Why is screening so important? Depression is a serious mental health concern. Children and adolescents with depression have a much higher chance of having depression as adults and carry a higher risk of suicide. Treatment of depression in children and adolescents can improve physical and emotional health, leading to healthy and productive lives<sup>9</sup>.

#### Screening to Detect Depression in Adolescents and Children:

Who and When to Screen:				
Age Range Frequency of Screening Screening Tools				
		PHQ-2 - Prior to office visit		
12 Years and Older	Annually	PHQ-A or PHQ-9 - During office visit		
		Short Mood & Feeling Questionnaire (SMFQ)		
		prior to office visit		
		Long Mood & Feelings Questionnaire (LMFQ)		
11 Years and Younger	When depression suspected	during office visit		

**Risk Factors for MDD:** Females, older age, family history of depression, prior history of depression, comorbid mental health or behavioral problems, chronic medical illness, obesity, ACEs, uncertainty about sexual orientation, low socioeconomic status, poor academic performance.

#### **Evaluation and Diagnosis of Depressive Disorders:**

#### DSM 5 TR Criteria for Major Depressive Disorder (MDD)

 Discreet episode of at least 2 weeks – of a clear change in mood for the worse (sadness/irritability) and at least 5 of the below criteria must be present for most of the day, nearly every day and must result in significant distress or functional impairment for the child.

Criteria for Major Depressive Disorder (MDD)		
Depressed Mood (Subjective or Observed)	Psychomotor Agitation or Retardation	
Loss of Interest/Pleasure in Activities	Fatigue or Loss of Energy	
Significant Unintentional Weight Loss or Gain	Feelings of Worthlessness or Excessive Guilt	
Decrease or Increase in Appetite	Decreased Concentration	
Insomnia or Hypersomnia	Recurrent Thoughts of Death/Suicide	

#### DSM 5 TR Criteria for Persistent Depressive Disorder

- Chronic form of Depression lasting > 1 year
- Symptoms occurring on most days
- Symptoms are similar to MDD, however less severe and less pervasive

#### DSM 5 TR Criteria for Disruptive Mood Dysregulation Disorder

- Symptoms must be recurrent and present for at least 12 months with no longer than 3 months symptom free
- Persistent irritable or angry mood most days of the week and in at least 2 settings
- Severe temper outbursts (behavioral/verbal) at least 3 times a week that are not in line with the situation or the child's developmental level
- Resulting in significant distress or functional impairment for the child
- Child must be  $\geq$  6 years old. Symptoms are usually present by age of 10

# **Best Practices**

#### Rule out/Differentials to be considered:

Medical Conditions	Medications	Substances/Toxins	Other Mental Health Conditions
Hypothyroidism	<ul> <li>Narcotic Analgesics</li> </ul>	Nicotine	ADHD
Mononucleosis	<ul> <li>Chemotherapy Agents</li> </ul>	Alcohol	Disruptive Behavior Disorders
• Anemia	<ul> <li>Cardiovascular Medications</li> </ul>	Cannabis	Anxiety
• Autoimmune Diseases	• Stimulants	Opiates	PTSD
Chronic Fatigue Syndrome	<ul> <li>Corticosteroids</li> </ul>	Cocaine	Bipolar Depression
• Migraines	<ul> <li>Immunosuppressants</li> </ul>	<ul> <li>Other Stimulants</li> </ul>	<ul> <li>Psychotic Disorders</li> </ul>
• Epilepsy	Oral Contraceptives	<ul> <li>Sedatives</li> </ul>	Autism Spectrum Disorder
• Asthma		Anabolic Steroids	Learning Disorders
• Inflammatory Bowel Disease		Carbon Monoxide	

#### **Depression Treatment Guidelines:**

Nonpharmaceutical Treatment Interventions for Depression:

Psycho	otherapy	Integrative Approaches
Older Children/Adolescents:	Younger Children:	
Individual Psychotherapy	Individual Psychotherapy	Somatic Therapies
<ul> <li>CBT (Gold Standard)</li> </ul>	<ul> <li>CBT (Gold Standard)</li> </ul>	<ul> <li>Biofeedback/Integrative Physical Therapy</li> </ul>
<ul> <li>Interpersonal Therapy</li> </ul>	<ul> <li>Interpersonal Therapy</li> </ul>	Somatic Experiencing
Modified CBT	<ul> <li>Play Therapy</li> </ul>	Supplementation
<ul> <li>Psychoanalytic</li> </ul>		• Omega-3 (Fish Oil), St. John's Wort, Many Others
+ many other options	Family Therapy	Other
	<ul> <li>Attachment Based</li> </ul>	Eletroconvulsive Therapy
Family Therapy	Parent-Child Interaction Therapy	<ul> <li>Transcranial Magnetic Stimulation</li> </ul>
		• Sleep Hygiene
Group Therapy	Group Therapy	Nutrition

Pharmaceutical Treatment Interventions for Depression:

SSRIs	SNRIS	MAOs/TCAs	Miscellaneous
Fluoxetine (FDA approved 8+)	Venalafaxine	Monoamine Oxidase Inhibitors	Dopamine Norepinephrine
Escitalopram (FDA approved 12+)	Venlafaxine XR	Phenelzine	Reuptake Inhibitors
Citalopram	Desvenlafaxine	Tranylcypromine	Bupriopion, Buprioprion XR or SR
Sertraline	Duloxetine	Isocarboxazid	Norepinephrine-Serotonin
Paroxetine		Tricyclic Antidepressants	Modulator
Fluvoxamine		Amitriptyline	Mirtazepine
Vilazodone		Doxepin	Seratonin Antagonist
		Imipramine	Reuptake Inhibitors
		Nortriptyline	Trazodone

#### **Indications for referral to Psychiatric Providers:**

Indications for Specialty Referral		
Suicidality or History of Suicide Attempts	Concerns for Mania	
Moderate to Severe Depression	Diagnostic Uncertainty	
Chronic and Recurrent Depression	Co-occurring Mental Health & Substance Use	
MDD with Psychotic Features	Co-occurring Mental Health & Personality Disorders	

These guidelines serve to assist in the management, documentation, and coding of clinical diagnoses. The intent of this document is to supplement, but not replace, the provider's clinical judgement.

#### Best Practice for Children or Adolescents with Anxiety

#### Why Screen and Treat Children or Adolescents with Anxiety?

Why is screening so important? Anxiety is a common mental health concern. Per the National Institutes of Mental Health estimation, 25% of youth ages 13-18 years old experience an anxiety disorder, with almost 6% of these youth experiencing severe anxiety. Treatment of anxiety in children and adolescents can improve physical and emotional health, leading to healthy and productive lives<sup>8</sup>.

#### Screening to Detect Anxiety in Adolescents and Children:

- USPSTF recommends screening for anxiety disorders in children and adolescents 8+ years.
- Screening occurs based on either parent or child self-reports symptoms OR based on practitioner observations/clinical history.

	Screening Tools		
•	Screen for Child Anxiety Related Disorders (SCARED) Spence Children's Anxiety Scale (SCAS) and Preschool Anxiety Scales Generalized Anxiety Disorder – 7 (GAD-7)	• •	Anxiety Pediatric Symptom Checklist Strengths and Difficulties Questionnaire American Psychiatric Association's Cross-Cutting Symptom Measures
Risk Factors for Anxiety Disorders in Children and Adolescents:			

Family history of anxiety disorders, exposure to violence/trauma, ACES, low socioeconomic status, social support, comorbid mental health, or behavioral concerns, etc.

#### **Evaluation and Diagnosis of Anxiety Disorders:**

There are 11 defined anxiety disorders in the DSM 5 TR. All the disorders cause clinically significant distress or impaired functioning for the individual. Some of the more common ones are:

DSM 5 Diagnosis	Symptoms	Time Duration
Generalized Anxiety Disorder	<ul> <li>Excessive anxiety or worry about events/activities</li> <li>1 or more of the following: Restlessness, fatigue, difficulty concentrating, irritability, muscle tension, sleep disturbance</li> </ul>	<ul> <li>Occurring more days than not for at least 6 months</li> </ul>
Panic Disorder	<ul> <li>Recurrent, unexpected panic attacks</li> <li>1 or more attacks followed by maladaptive behavior changes or worry related to panic attacks</li> <li>Intense fear or discomfort peaking withing minutes with <i>4 or more of the following:</i></li> <li>Palpitations, sweating, trembling, shortness of breath, choking, chest pain, nausea, feeling faint or dizzy, chills and/or hot flashes, paresthesia, derealization/depersonalization, fear of losing control/dying</li> </ul>	• At least 1 month of persistent worry or maladaptive behavior changes related to panic attacks
Social Anxiety Disorder	<ul> <li>Excessive anxiety or worry about events/activities</li> <li>1 or more of the following: Restlessness, fatigue, difficulty concentrating, irritability, muscle tension, sleep disturbance</li> </ul>	<ul> <li>Persistent, lasting for at least 6 months</li> </ul>
Separation Anxiety Disorder	<ul> <li>Developmentally inappropriate anxiety/fear of separation from attachment figure</li> <li><i>3 or more of the following:</i>         Recurrent excessive distress when anticipating or experiencing separation; persistent and excessive worry about loss and harm; persistent and excessive worry about an event causing separation; persistent reluctance or refusal to go out because of separation fear; persistent and excessive fear or reluctance to be alone or without attachment figure; persistent reluctance or refusal to sleep away from home or be away from attachment figure; repeated separation nightmares; repeated complaints of physical symptoms when separation occurs or is anticipated     </li> </ul>	• Lasting at least 4 weeks

# **Best Practices**

#### Rule out/Differentials to be considered:

Medical Conditions	Medications	Substances/toxins	Mental Health Disorders
<ul> <li>Hyperthyroidism</li> <li>Caffeinism</li> <li>Migraines</li> <li>Asthma</li> <li>Diabetes</li> <li>Chronic pain/illness</li> <li>Hypoglycemic episodes</li> <li>Hypoxia</li> <li>Pheochromocytoma</li> <li>Central Nervous Systems Disorders</li> <li>Cardiac arrhythmias</li> <li>Cardiac valvular disease</li> <li>Systemic lupus erythematosus</li> <li>Allergic reactions</li> <li>Dysmenorrhea</li> </ul>	<ul> <li>Bronchodilators</li> <li>Nasal decongestants and other sympathomimetics</li> <li>Antihistamines</li> <li>Steroids</li> <li>Dietary supplements</li> <li>Antidepressants</li> <li>Antipsychotics</li> <li>Stimulants</li> <li>Withdrawal from benzodiazepines (esp. short-acting)</li> </ul>	<ul> <li>Cannabis</li> <li>Cocaine</li> <li>Anabolic Steroids</li> <li>Hallucinogens</li> <li>Phencyclidine</li> <li>Withdrawal from nicotine, alcohol, or caffeine</li> <li>Exposure to organophosphates</li> <li>Ingestion of metals (lead, arsenic, etc.)</li> </ul>	<ul> <li>ADHD</li> <li>Obsessive- Compulsive disorder</li> <li>Psychotic disorder</li> <li>Autism Spectrum disorder</li> <li>Learning disorders</li> </ul>

#### **Anxiety Treatment Guidelines:**

Nonpharmaceutical Treatment Interventions for Anxiety:

Psychotherapy		Integrative Approaches
Older Children/Adolescents:	Younger Children:	
Individual Psychotherapy	Individual Psychotherapy	Somatic Therapies
<ul> <li>CBT (Gold Standard)</li> </ul>	<ul> <li>CBT (Gold Standard)</li> </ul>	<ul> <li>Biofeedback/Integrative Physical Therapy</li> </ul>
<ul> <li>Interpersonal Therapy</li> </ul>	<ul> <li>Interpersonal Therapy</li> </ul>	Somatic Experiencing
Modified CBT	Play Therapy	Supplementation
<ul> <li>Psychoanalytic</li> </ul>		• Omega-3 (Fish Oil), St. John's Wort, Many Others
+ many other options	Family Therapy	Other
	<ul> <li>Attachment Based</li> </ul>	Eletroconvulsive Therapy
Family Therapy	Parent-Child Interaction Therapy	Transcranial Magnetic Stimulation
		• Sleep Hygiene
Group Therapy	Group Therapy	Nutrition

Pharmaceutical Treatment Interventions for Anxiety:

SSRIs		SNRIs	Miscellaneo	ous	
Fluoxetine	Escitalopram	Venlafaxine	Unknown Mee	chanism of action	Antihistamines
Citalopram	Sertraline	Venlafaxine XR	Buspirone		Diphenhydramine
Paroxetine	Fluvoxamine	Desvenlafaxine	Hydroxyzine		
Vilazodone		Duloxetine <b>(FDA</b>	Benzodiazepi	nes	Beta blockers
		approved 7+)	Alprazolam	Lorazepam	Propranolol
			Diazepam	Clonazepam	

Indications for Specialty Referral			
Suicidality or History of Suicide Attempts	Moderate to Severe Symptoms		
Chronic or Recurrent Symptoms	Diagnostic Uncertainty		
Co-occurring Mental Health and Personality Disorders	Co-occurring Mental Health and Substance Use		
	Disorders		

These guidelines serve to assist in the management, documentation, and coding of clinical diagnoses. The intent of this document is to supplement, but not replace, the provider's clinical judgement.

Banner Plans & Networks Confidential Information

# **Tip Sheets**

# **Tip Sheets**

# **Depression & Anxiety Screening Tips**

Best Practices:

- All patients should be screened for depression at least annually.
- For pre-appointment screening, please use the PHQ-2.
- The PHQ-9 questions regarding suicidality need to be reviewed and acted upon by the provider, so distributing in advance is not advised.
- Printable copies of screening tests in multiple languages are available for download from <a href="https://www.phqscreeners.com/select-screener">https://www.phqscreeners.com/select-screener</a>
- Laminate copies of the screening tools for patients to complete with wipe-off marker while in the exam area waiting for their provider.
  - After the patient has completed the questionnaire on the laminated screening tool the laminated tool should be scored and inputted into the patient's chart prior to cleaning for the next patient's use.
- Have a tablet with screening tools for patient to use.
- As with all tools, clinical judgement should be used when interpreting results.

# **Documenting Follow-ups**

#### How to Document Follow-ups?

Follow-Up Plan: Documented follow-up for a positive depression screening must include one or more of the following:

- Referral to a provider for additional evaluation and assessment to formulate a follow-up plan for a positive depression screen
- Pharmacological interventions
- Other interventions or follow-up for the diagnosis or treatment of depression

# **Tip Sheets**

# PHQ-9 Interpretation, Treatment & Determining Remission

PHQ-9 total score	Depression Severity	Actions
0-4	None or minimal depression	Treatment typically is not needed.
5-9	Mild depression	<ul> <li>Monitor and repeat PHQ-9 in 6-12 months, or sooner if clinically indicated.</li> <li>Consider possible treatment based on duration and severity of symptoms, as well as patient preferences.</li> </ul>
10-14	Moderate depression	<ul> <li>Repeat PHQ-9 in 4-6 weeks to assess symptom progression and/or response to treatment.</li> <li>Consider counseling referral and possible medication treatment based on severity and duration of symptoms, as well as patient preferences.</li> <li>Symptoms that are present for 2 years or more constitute chronic depression, consider pharmacotherapy.</li> <li>Active treatment is indicated if symptoms have been present for more than one month and are associated with significant functional impairment.</li> </ul>
15-19	Moderately severe depression	<ul> <li>Repeat PHQ-9 in 4-6 weeks to assess treatment response.</li> <li>Treatment generally is indicated with medication, therapy, or both.</li> </ul>
20-27	Severe depression	<ul> <li>Repeat PHQ-9 within 4-6 weeks, or sooner if clinically indicated, to assess treatment response.</li> <li>Prompt initiation of pharmacotherapy is indicated.</li> <li>Consider expedited referral to mental health specialists for psychotherapy and collaborative medical management.</li> </ul>

# **PHQ-9** Scoring After 4-6 Weeks of Treatment with an Antidepressant at an Adequate Dose

PHQ 9 Change	Action
Drop of 5 points or more OR 50% Reduction in	Adequate response. No treatment changes needed.
Score	Follow up in 4-6 weeks.
Drop of 2-4 points	Likely inadequate response.
	Consider increase in antidepressant dose.
	Follow up in 4-6 weeks.
Drop of 0-1 points or increased score	Increase dose, add an augmenting agent, or switch to an
	alternative antidepressant.
	Consider counseling, if not already in place.
	Consider psychiatric consultation.
	Follow up in 4-6 weeks.

#### **Evaluating Treatment Response**

Follow Up PHQ 9 Score	Action
Drop of 5 or more points after 3 months of	Clinically Significant Response
treatment	Continue to monitor every 6 months or as clinically indicated
Score of 6-10	Partial remission
	Continue to monitor every 6 months or as clinically indicated
Score of 1-5	Remission
	Continue to monitor every 6-12 months or as clinically
	indicated

See Behavioral Health Toolkit Main Document for References and Additional Resources

# Behavioral Health Coding & Documentation

In 2008, the World Health Organization (WHO) ranked major depressive disorder (MDD) third in causes of long-term disease burdens. They projected that MDD will move to first place by 2030. Therefore, selecting the most specific and appropriate diagnosis for patients is essential for telling the best patient story, identifying patients who may need additional care dollars to manage their disease process, and for making sure our patients don't fall through the proverbial "crack".

#### **Diagnosis Code Selection and Documentation Tips**

The provider should include the below qualifiers to the diagnosis code and documentation. If it is unclear, query the provider.

- Type (episode):
  - **Single episode**: First time the patient meets the criteria for MDD and has no history of a prior event. If the patient **never** experiences a break in symptoms and continues to meet the criteria for MDD, then the single episode remains appropriate.
  - Recurrent episode: An episode is considered recurrent when there is an interval of at least two consecutive months between separate episodes during which criteria are not met for MDD. Multiple episodes of MDD exist.
- Severity:
  - Mild: typically 2 or 3 symptoms are present.
  - **Moderate**: four or more symptoms are present, difficulty with activities of daily living (ADLs).
  - **Severe**: With or without psychotic features. Unable to complete ADLs, thoughts or actions of suicide may be present. Provider documentation is essential.
- Status:
  - **In remission**: Determined by the treatment level of the patient. Is the patient actively being treated for MDD (i.e., receiving counseling and/or taking anti-depressive medication and is "stable").
  - **Partial remission**: Occasional symptoms from a previous major depressive episode without meeting full criteria or hiatus lasting less than two months without any significant symptoms.
  - **Full remission**: No significant signs or symptoms of the disturbance present during the past two months. The patient may still be receiving treatment for prevention of additional episodes.
  - **History of**: The patient is no longer receiving active treatment for the MDD and is stable.
- Specifiers, if applicable, such as:
  - With anxious distress
  - With mixed features
  - With melancholic features
  - With peripartum onset
  - With seasonal pattern

There are significant changes noted in the V28 CMS – HCC risk adjustment model regarding MDD. Most notably is the removal of the risk adjustment factor (RAF) value to MDD diagnoses that are:

- Mild
- In remission

Banner Plans & Networks Confidential Information

- In partial remission
- In full remission
- Unspecified

#### **Major Depressive Disorder ICD-10s**

ICD-10- CM codes	Description	ICD-10- CM codes	Description
F32.0	Major depressive disorder, single episode, mild	F33.0	Major depressive disorder, recurrent, mild
F32.1 *	Major depressive disorder, single episode, moderate	F33.1 *	Major depressive disorder, recurrent, moderate
F32.2 *	Major depressive disorder, single episode, severe without psychotic features	F33.2 *	Major depressive disorder, recurrent, severe without psychotic features
F32.3 *	Major depressive disorder, single episode, severe with psychotic features	F33.3 *	Major depressive disorder, recurrent, severe with psychotic features
F32.4	Major depressive disorder, single episode, in partial remission	F33.40	Major depressive disorder, recurrent, in remission, unspecified
F32.5	Major depressive disorder, single episode, in full remission	F33.41	Major depressive disorder, recurrent, in partial remission
F32.81	Premenstrual dysphoric disorder	F33.42	Major depressive disorder, recurrent, in full remission
F32.89	Other specified depressive episodes	F33.8	Other recurrent depressive episodes
F32.9	Major depressive disorder, single episode, unspecified	F33.9	Major depressive disorder, recurrent, unspecified
F32.A	Depression, unspecified	F34.1	Persistent depressive disorder (Persistent Dysthymic disorder)

"\*" = diagnoses that risk adjust in the V28 risk adjustment model.

#### **Appropriate Documentation:**

When selecting the best diagnosis for your patient, code what you know, be as specific as possible, and review any notes from the specialist. It is recommended to use the same diagnoses that the specialist uses if the patient meets the criteria. Remember the MEAT (Monitor, Evaluate, Assess/Address, and Treat) mnemonic will help ensure you include the pertinent information in your note. Below is an example of good documentation.

#### Major depressive disorder, recurrent, moderate (F33.1)

Ms. M is seen for medication management for her MDD. The patient states that she "can't make it through the day" without her escitalopram, and she feels more on edge. PHQ-9 today is a 12 which is lower than the 14 at the last visit. Ms. M appears to be more anxious and restless today, and the GAD-7 score was a 6. She states that work has been very busy, and her children are stressing her out.

Pt has been on escitalopram 10mg for the past year and does not want to add any more medications to her routine. Referral to psychiatry.

Questions regarding Risk Adjustment coding, documentation, and billing – email <u>BPN.RiskAdjustmentLeadershipTeam@bannerhealth.com</u>

# Provider & Patient Resources

#### \*Crisis Resources

#### What is a Behavioral Health Emergency?

- When you think you are having a crisis or any situation where you believe you might hurt yourself or someone else because of your mood or thinking.
- When someone's thinking changes rapidly to the point where the person is not able to recognize reality from fantasy. Sometimes the person does not realize what is happening and may not want help.

# If patient has an **IMMEDIATE** need, please call the appropriate **CRISIS LINE** or **911**:

#### **National 24-Hour Crisis Hotlines**

Suicide & Crisis Lifeline: 988

National Suicide Prevention Lifeline: 800-273-8255

National Substance Use & Disorder Issues Referral & Treatment Hotline: 800-662-4357

Teen Lifeline - Phone or Text: 602-248-8336

SAMHSA Crisis Text Line: Text HOME to 741741

#### **Suicide & Crisis Hotlines by County**

Maricopa County: 800-631-1314 or 602-222-9444

Apache, Gila, Mohave, Navajo & Yavapai: 877-756-4090

Cochise, Graham, Greenlee, La Paz, Pima, Pinal, Santa Cruz & Yuma: 866-495-6735

#### Warm Lines by County

A Warm Line is a confidential, free phone service offering mental health support. Unlike a crisis line, they are not intended for emergency situations.

Gila & Maricopa County: 602-347-1100

Pima County: 520-770-9909

Cochise, Graham, Greenlee, La Paz, Pima, Pinal, Santa Cruz & Yuma: 844-733-9912

Tribal Warm Line for American Indian Community Members: 855-728-8630

Banner - University Health Plans - Behavioral Health Care Management & Provider Referral



2701 E. Elvira Road, Tucson, Arizona 85756 (800) 582-8686 • TTY 711 • Fax (520) 874-5555 www.BannerUHP.com

#### PCP Referral to Behavioral Health Provider

#### How can a Behavioral Health (BH) Provider help?

Banner – University Health Plans (BUHP) is committed to coordination of care for patients/members to ensure optimal integrated care to meet their needs. Many of our members have complex behavioral health and physical health conditions that may require multiple providers to communicate their treatment approaches and interventions to improve the member's care.

BH Providers offer a wide array of evidence-based services to help meet each member's needs to promote their overall wellbeing. BH Providers can help support members who are struggling with mental health symptoms and can assist them in making behavioral changes. Members who complete an intake with a BH Provider agency receive a comprehensive assessment that helps identify their unmet needs and treatment objectives, provides an initial diagnosis and identifies potential interventions. A BH Provider Case Manager is assigned to regularly reach out to the patient to reassess symptom severity and connect them to clinically appropriate services to help the member reach their goals. In addition to formal services, BH Providers help meet cultural needs and empower members by connecting them to community supports to encourage long-term wellness.

#### Who can benefit from a referral to a BH Provider?

Members may benefit from a referral to a BH Provider if their behavioral health needs require extensive or specialized services beyond the primary care provider's scope. Examples of support that BH providers can offer include the following:

- Counseling, psychotherapy or a specialized therapy
- Support for co-occurring conditions (e.g. physical, behavioral, substance use, and/or developmental)
- Intensive wrap-around services from direct support providers which may support members who have recently
  attempted to harm self and/or others
- Psychiatric, psychological or neuropsychological testing and implementation of recommendations
- Support for complex trauma
- Care coordination for members at risk of BH hospitalization or BH residential services
- Medication for a diagnosis other than ADHD, Anxiety, Depression and Opioid Use Disorder

#### How and when to refer to a BH Provider?

If BUHP members require medication for certain limited behavioral health disorders (Anxiety, Depression, Attention Deficit Hyperactive Disorder (ADHD) and Opioid Use Disorder), they may obtain medication from a primary care provider. All other psychiatric diagnoses must be referred to a BUHP contracted BH Provider.

Referrals can be made with the attached PCP Referral to BH Provider form, which includes general information about the member, referring PCP information and the chief complaint/symptoms resulting in the referral. Once the referral is submitted by email, a BUHP Care Manager will follow up on member intake and enrollment with the BH Provider to verify the member is connected to services. The referral is not required if the member would prefer to contact a BH Provider directly or to outreach BUHP Customer Care at (800) 582-8686. The benefit of completing the included referral is that a BUHP Care Manager will be assigned to the member for additional support as needed.

Members suspected as having an autism diagnosis can be managed through this referral process or directly referred to a specialized Autism Spectrum Disorder (ASD) diagnosing provider located at: https://www.banneruhp.com/resources/autism-spectrum-disorder.

> Banner – University Family Care/ACC | Banner – University Family Care/ALTCS Banner – University Care Advantage HMO SNP

#### Banner Plans & Networks Confidential Information



2701 E. Elvira Road, Tucson, Arizona 85756 (800) 582-8686 • TTY 711 • Fax (520) 874-5555 www.BannerUHP.com

#### PCP Referral to Behavioral Health Provider

This patient receiving medical care services at our practice is in need of a Behavioral Health Assessment.

Urgency of Referral:  Routine (Member must be seen with	in 7 days)
Urgent (Member must be seen within	n 24 hours)
Date:	AHCCCS ID:
Member's Name:	DOB:
Phone:	Address:
Legal Guardian (if applicable): 🗆 Parent/Guardianship	Guardian's Name (if applicable):
Department of Child Safety	
Member's Preferred Language:	Guardian's Preferred Language (if applicable):
Payer Source:  Banner–University Family Care (ACC)	
Banner–University Family Care (ALTCS)	
Banner–University Care Advantage (HMO SI	NP)
Section 2: Referring PCP Information	
Primary Care Provider's Name:	Practice Name:
Address:	Phone:
Fax:	Email:
Section 3: Referral Information	
Complaint/Symptoms Resulting in Referral:	□Obsessions/compulsions
Anxiety/panic	Personality disordered behaviors
Cognitive decline/dementia	□Violence/aggressive/oppositional behavior
	Other behavioral health symptoms:
Developmental delay	Psychosis (auditory/visual hallucinations, delusions)*
Difficulty with attention, hyperactivity or impulsivity	□Suicidal ideation*
Post-traumatic stress/trauma/abuse	□Homicidal ideation*
Eating disorder behavior	*If patient is a danger to self or others, or otherwise in need
Substance use type:	of IMMEDIATE support, please call the appropriate CRISIS
	LINE below.
Current Diagnoses:	Current Medications:

If the patient has an IMMEDIATE need, please call the appropriate CRISIS LINE:

Maricopa County: (800) 631-1314 or (602) 222-9444

Gila County: (877) 756-4090

Pima, Pinal, Yuma, La Paz, Cochise, Graham, Greenlee and Santa Cruz Counties: (866) 495-6735

Email routine and urgent referrals to: BUHPCareMgmtBHMailbox@bannerhealth.com

Banner – University Family Care/ACC | Banner – University Family Care/ALTCS Banner – University Care Advantage HMO SNP

# Banner - Aetna Mental Wellbeing Resource Center

#### Let's make every day better and brighter

Nothing should stand in the way of good mental health. So, if you are in need or caring for someone who is, you can turn to us for information, inspiration, and support when you're ready. Whatever you are facing, you're not in this alone.





Make an appointment with a Behavioral Health Provider

Find educational videos on:

- Attention Deficit Hyperactivity Disorder
- Depression
- Bipolar
- Anxiety
- Relationships
- Substance Misuse
- Suicide
- And More

Find Virtual Mental Health Care

Make a video appointment with a provider at MDLIVE includes psychiatrists, social workers, and marriage counselors.

Join a video counseling and coaching program

Check in on yourself – Self assessments for:

- Anxiety
- Depression
- Quick Mind Check



### Humana Behavioral Health Consult Team



#### When To Refer

Common referral conditions listed below; from rounds consultation to risk assessment for behavioral needs

Severity and/or Complex BH Needs				
Addiction or SUD Treatment	<ul> <li>Special need population – BH treatment</li> </ul>			
Member crisis but no immediate risk	needed			
Serious Mental Illness (SMI)	• BH symptoms complicating chronic physical			
Eating Disorders	health condition			
• Pregnancy or recent birth complicated by BH	• BH symptoms significantly affecting daily life			
needs	Psychiatric evaluation needed			
Consultation on appropriate level of care	Early indicators of BH Symptoms			
BH provider access issues	Other reasons based on clinical judgement			

#### Arizona Perinatal Psychiatry Consult Line



# Arizona Perinatal Psychiatry Access Line

Is your patient pregnant or postpartum and struggling with substance use and/or their mental health?

# Call 888-290-1336

to consult with perinatal psychiatrists who will provide free clinical guidance, M-F, 12:30 p.m.-4:30 p.m.

APAL is a statewide perinatal psychiatry access line. We assist medical providers in caring for their pregnant and postpartum patients with mental health and substance use disorders. Perinatal psychiatrists are available by phone to answer your questions and review treatment options.

APAL.arizona.edu



team@apal.arizona.edu

# \lambda Banner Plans & Networks

### Banner Health Network Pyx Health Program



Pyx Health builds connections with each user to bridge the gap between their precise needs and the right resources — all while providing a friend who cares.

**Pyx Health is proud to partner with your organization to address loneliness and social isolation, the root cause of myriad physical and behavioral health problems.** Through the combination of an engaging mobile experience and friendly humans at the Compassionate Support Center, Pyx Health supports users outside the care setting.

You have no idea how good it felt to answer the phone and have someone ask me, 'How are you feeling today?' It feels like I really do have friends.

Maria, Pyx Health member

#### » Access resources, screenings, and SDOH support

In addition to providing quick and easy access to your resources, the Pyx Health program also regularly screens for loneliness, depression, anxiety, and SDOH needs (housing, food, childcare, transportation, etc), and offers real-time help to meet users' needs.

#### » Chat with Pyxir, the friendly chatbot

Pyxir and his best friend Rudy provide 24/7 companionship, humor, and uplifting support with loneliness, anxiety, motivation, and more.

#### » Get human support

Our Compassionate Support Center staff is ready to assist users over the phone during weekday business hours — making them feel heard, seen, and helped in times of need with a connection to your organization or a community-based organization. There is no limit to the duration or number of calls between users and our trained staff.

Thank you for all your help. I was able to find resources on that site. I actually found MOPS, a support group for moms. I was looking for that too.

Jenny, Pyx Health member

#### Signing up is easy

The app is available at the App Store and Google Play store, or on the web at pyxhealth.com/store-download. Those without a smartphone can receive services via telephone at 1-855-499-4777.





pyxhealth.com • 1-855-499-4777

Banner Health Network.

# **Screening Tools**

# PHQ – 2 Short Depression Screening Tool

\_ \_

#### Patient Health Questionnaire-2 (PHQ-2)

#### Instructions:

Please respond to each question.

Over the last 2 weeks,	how often have you bee	en bothered by any of the	ne following problems?
Give answe	rs as 0 to 3, using this sca	ale:	
0=Not at all;	1=Several days; 2=Mor	e than half the days; 3=N	learly every day
1. Little interest or	pleasure in doing thing	s	
0	<b>1</b>	2	3
2. Feeling down, d	epressed, or hopeless		
0	<b>1</b>	2	3
Instructions Clinic personnel will follo	ow standard scoring to cal	lculate score based on re	sponses.

Total	score:
TOLA	score.

Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display or distribute.

### PHQ-9 Depression Screening Tool

#### PATIENT HEALTH QUESTIONNAIRE-9 (PHQ-9)

Over the last 2 weeks, h by any of the following p (Use " " to indicate your		ed Not at all	Several days	More than half the days	Nearly every day
1. Little interest or pleasur	e in doing things	0	1	2	3
2. Feeling down, depress	ed, or hopeless	0	1	2	3
3. Trouble falling or stayin	g asleep, or sleeping too much	0	1	2	3
4. Feeling tired or having	little energy	0	1	2	3
5. Poor appetite or overea	ting	0	1	2	3
<ol> <li>Feeling bad about your have let yourself or you</li> </ol>	self — or that you are a failure or ir family down	0	1	2	3
7. Trouble concentrating on newspaper or watching	on things, such as reading the television	0	1	2	3
noticed? Or the opposition	slowly that other people could have the — being so fidgety or restless ving around a lot more than usual	0	1	2	3
<ol> <li>Thoughts that you woul yourself in some way</li> </ol>	d be better off dead or of hurting	0	1	2	3
	For office	CODING+		•+	
			-	Total Score:	
	roblems, how <u>difficult</u> have the s at home, or get along with oth		ade it for	you to do y	our
Not difficult at all	Somewhat difficult	Very difficult		Extreme difficul	

Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display, or distribute.

# GAD – 7 Anxiety Screening Tool

#### GAD-7

Over the <u>last 2 weeks</u> , how often have you been bothered by the following problems?	Not at all	Several days	More than half the days	Nearly every day
(Use "✔" to indicate your answer)				
1. Feeling nervous, anxious or on edge	0	1	2	3
2. Not being able to stop or control worrying	0	1	2	3
3. Worrying too much about different things	0	1	2	3
4. Trouble relaxing	0	1	2	3
5. Being so restless that it is hard to sit still	0	1	2	3
6. Becoming easily annoyed or irritable	0	1	2	3
<ol> <li>Feeling afraid as if something awful might happen</li> </ol>	0	1	2	3
(For office coding: Total Sco	ore T	=	+ •	+)

Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from Pfizer Inc. No permission required to reproduce, translate, display, or distribute.

# Geriatric Depression Scale (GDS)- Short Form

#### **Patient Version**

### Geriatric Depression Scale (Short Form) Self-Rated Version

Patient's Name:

Date:

#### Instructions: Choose the best answer for how you felt over the past week.

No.	Question	Answer	Score
1.	Are you basically satisfied with your life?	YES / NO	
2.	Have you dropped many of your activities and interests?	YES / NO	
3.	Do you feel that your life is empty?	YES / NO	
4.	Do you often get bored?	YES / NO	
5.	Are you in good spirits most of the time?	YES / NO	
6.	Are you afraid that something bad is going to happen to you?	YES / NO	
7.	Do you feel happy most of the time?	YES / NO	
8.	Do you often feel helpless?	YES / NO	
9.	Do you prefer to stay at home, rather than going out and doing new things?	YES / NO	
10.	Do you feel you have more problems with memory than most people?	YES / NO	
11.	Do you think it is wonderful to be alive?	YES / NO	
12.	Do you feel pretty worthless the way you are now?	YES / NO	
13.	Do you feel full of energy?	YES / NO	
14.	Do you feel that your situation is hopeless?	YES / NO	
15.	Do you think that most people are better off than you are?	YES / NO	
		TOTAL	

(Sheikh & Yesavage, 1986)

#### **GDS Scoring**

Answers indicating depression are in bold and italicized; score one point for each one selected. A score of 0 to 5 is considered normal. A score greater than 5 suggests depression.

No.	Question	Answer	Score
1.	Are you basically satisfied with your life?	YES / NO	
2.	Have you dropped many of your activities and interests?	YES / NO	
3.	Do you feel that your life is empty?	YES / NO	
4.	Do you often get bored?	Yes / No	
5.	Are you in good spirits most of the time?	YES / NO	
6.	Are you afraid that something bad is going to happen to you?	Yes / No	
7.	Do you feel happy most of the time?	YES / NO	
8.	Do you often feel helpless?	Yes / No	
9.	Do you prefer to stay at home, rather than going out and doing new things?	Yes / No	
10.	Do you feel you have more problems with memory than most people?	Yes / No	
11.	Do you think it is wonderful to be alive?	YES / NO	
12.	Do you feel pretty worthless the way you are now?	YES / NO	
13.	Do you feel full of energy?	YES / NO	
14.	Do you feel that your situation is hopeless?	YES / NO	
15.	Do you think that most people are better off than you are?	Yes / No	
		TOTAL	

(Sheikh & Yesavage, 1986)

### Edinburgh Postnatal Depression Scale (EPDS)

#### **Patient Version**

# Edinburgh Postnatal Depression Scale<sup>1</sup> (EPDS)

Name:	Address:
Your Date of Birth:	
Baby's Date of Birth:	Phone:
	we would like to know how you are feeling. Please check elt IN THE PAST 7 DAYS, not just how you feel today.
Here is an example, already completed.	
	have felt happy most of the time" during the past week. other questions in the same way.
In the past 7 days:	
<ol> <li>I have been able to laugh and see the funny side of         <ul> <li>As much as I always could</li> <li>Not quite so much now</li> <li>Definitely not so much now</li> <li>Not at all</li> </ul> </li> <li>I have looked forward with enjoyment to things         <ul> <li>As much as I ever did</li> <li>Rather less than I used to</li> <li>Definitely less than I used to</li> <li>Hardly at all</li> </ul> </li> <li>*3. I have blamed myself unnecessarily when things</li> </ol>	<ul> <li>f things</li> <li>*6. Things have been getting on top of me <ul> <li>Yes, most of the time I haven't been able to cope at all</li> <li>Yes, sometimes I haven't been coping as well as usual</li> <li>No, most of the time I have coped quite well</li> <li>No, I have been coping as well as ever</li> </ul> </li> <li>*7 I have been so unhappy that I have had difficulty sleeping <ul> <li>Yes, most of the time</li> <li>Yes, sometimes</li> <li>Not very often</li> <li>No, not at all</li> </ul> </li> </ul>
went wrong <ul> <li>Yes, most of the time</li> <li>Yes, some of the time</li> <li>Not very often</li> <li>No, never</li> </ul>	*8 I have felt sad or miserable □ Yes, most of the time □ Yes, quite often □ Not very often □ No, not at all
<ul> <li>I have been anxious or worried for no good reason</li> <li>No, not at all</li> <li>Hardly ever</li> <li>Yes, sometimes</li> <li>Yes, very often</li> </ul>	*9 I have been so unhappy that I have been crying □ Yes, most of the time □ Yes, quite often □ Only occasionally □ No, never
<ul> <li>*5 I have felt scared or panicky for no very good reaso</li> <li>Yes, quite a lot</li> <li>Yes, sometimes</li> <li>No, not much</li> <li>No, not at all</li> </ul>	*10 The thought of harming myself has occurred to me Uses, quite often Sometimes Hardly ever Never

Administered/Reviewed by \_\_\_\_

Date \_\_\_\_

<sup>1</sup>Source: Cox, J.L., Holden, J.M., and Sagovsky, R. 1987. Detection of postnatal depression: Development of the 10-item Edinburgh Postnatal Depression Scale. British Journal of Psychiatry 150:782-786.

<sup>2</sup>Source: K. L. Wisner, B. L. Parry, C. M. Piontek, Postpartum Depression N Engl J Med vol. 347, No 3, July 18, 2002, 194-199

#### **EPDS Scoring**

#### Edinburgh Postnatal Depression Scale<sup>1</sup> (EPDS)

Postpartum depression is the most common complication of childbearing.<sup>2</sup> The 10-question Edinburgh Postnatal Depression Scale (EPDS) is a valuable and efficient way of identifying patients at risk for "perinatal" depression. The EPDS is easy to administer and has proven to be an effective screening tool.

Mothers who score above 13 are likely to be suffering from a depressive illness of varying severity. The EPDS score should not override clinical judgment. A careful clinical assessment should be carried out to confirm the diagnosis. The scale indicates how the mother has felt **during the previous week**. In doubtful cases it may be useful to repeat the tool after 2 weeks. The scale will not detect mothers with anxiety neuroses, phobias or personality disorders.

Women with postpartum depression need not feel alone. They may find useful information on the web sites of the National Women's Health Information Center <<u>www.4women.gov</u>> and from groups such as Postpartum Support International <<u>www.chss.iup.edu/postpartum</u>> and Depression after Delivery <<u>www.depressionafterdelivery.com</u>>.

SCORING
QUESTIONS 1, 2, & 4 (without an *) Are scored 0, 1, 2 or 3 with top box scored as 0 and the bottom box scored as 3.
QUESTIONS 3, 5-10 (marked with an *) Are reverse scored, with the top box scored as a 3 and the bottom box scored as 0. Maximum score: 30 Possible Depression: 10 or greater
Always look at item 10 (suicidal thoughts)
Users may reproduce the scale without further permission, providing they respect copyright by quoting the names of the authors, the title, and the source of the paper in all reproduced copies.

#### Instructions for using the Edinburgh Postnatal Depression Scale:

- The mother is asked to check the response that comes closest to how she has been feeling in the previous 7 days.
- 2. All the items must be completed.
- Care should be taken to avoid the possibility of the mother discussing her answers with others. (Answers come from the mother or pregnant woman.)
- The mother should complete the scale herself, unless she has limited English or has difficulty with reading.

<sup>1</sup>Source: Cox, J.L., Holden, J.M., and Sagovsky, R. 1987. Detection of postnatal depression: Development of the 10-item Edinburgh Postnatal Depression Scale. *British Journal of Psychiatry* 150:782-786.

<sup>2</sup>Source: K. L. Wisner, B. L. Parry, C. M. Piontek, Postpartum Depression N Engl J Med vol. 347, No 3, July 18, 2002, 194-199

# PHQ – A (PHQ-9 Modified for Adolescents)

# PHQ-9 modified for Adolescents (PHQ-A)

Name:	Clinician:		Dates	:	
<b>Instructions:</b> How often have you been bothered by each of the following symptoms during the past <u>two</u> <u>weeks</u> ? For each symptom put an " <b>X</b> " in the box beneath the answer that best describes how you have been feeling.					
		(0) Not at all	(1) Several days	(2) More than half the days	(3) Nearly every day
	ed, irritable, or hopeless?				
<ol><li>Little interest or pleasur</li></ol>					
<ol><li>Trouble falling asleep, s much?</li></ol>	staying asleep, or sleeping too				
4. Poor appetite, weight lo					
5. Feeling tired, or having					
	self – or feeling that you are a let yourself or your family				
<ol> <li>Trouble concentrating or reading, or watching TV</li> </ol>					
	slowly that other people could				
Or the opposite – being	so fidgety or restless that you				
were moving around a l					
<ol> <li>Thoughts that you woul hurting yourself in some</li> </ol>	d be better off dead, or of e way?				
In the <b>past year</b> have you fe	elt depressed or sad most days,	even if you fel	t okay someti	mes?	
□Yes	□No				
	of the problems on this form, how of things at home or get along v			ems made it fo	or you to
□Not difficult at all	Somewhat difficult	Very difficult	Extren	nely difficult	
Has there been a time in the	e past month when you have ha	d serious thou	ights about er	nding your life?	?
□Yes	□No				
Have you EVER, in your WHOLE LIFE, tried to kill yourself or made a suicide attempt?					
□Yes	□No				
**If you have had thoughts t this with your Health Care C	hat you would be better off dead linician, go to a hospital emerge	or of hurting y ncy room or c	yourself in sor all 911.	ne way, please	e discuss

Office use only:

Severity score:

Modified with permission from the PHQ (Spitzer, Williams & Kroenke, 1999) by J. Johnson (Johnson, 2002)

# SMFQ – Short Mood & Feelings Questionnaire

The SMFQ is designed to measure core depressive symptomology in children and adolescents aged 6-17 years old. There are two versions, one for the patient responses and one for parent or caregiver responses. There are no prescribed cut points for the SMFQ; however higher scores (over 12), suggest greater severity in depression symptoms. Providers should use their clinical judgement and discretion.

#### **Self-Reported**

# Short Mood and Feelings Questionnaire

This form is about how you might have been feeling or acting recently.

For each question, please check how much you have felt or acted this way in the past two weeks.

If a sentence was true about you most of the time, check TRUE.

- If it was only sometimes true, check SOMETIMES.
- If a sentence was not true about you, check NOT TRUE.

	NOT TRUE	SOMETIMES	TRUE
1. I felt miserable or unhappy			ū
2. I didn't enjoy anything at all		ū	
3. I felt so tired I just sat around and did nothing		ū	
4. I was very restless		ū	
5. I felt I was no good any more			
6. I cried a lot		D.	
7. I found it hard to think properly or concentrate	ū	ū	
8. I hated myself		ū	
9. I was a bad person			
10. I felt lonely		ū	٩
11. I thought nobody really loved me	ū.	ū	ū
12. I thought I could never be as good as other kids		ū	ū
13. I did everything wrong	ū		

Copyright Adrian Angold & Elizabeth J. Costerllo, 1987; Developed Epidemiology Program, Duke University Reproduced with permission from developer, may be reproduced for use with one's own patients.

#### **Parent or Caregiver Reported**

Parent Report Version - SMFQ

# Short Mood and Feelings Questionnaire

This form is about how your child may have been feeling or acting recently.

For each question, please check how much she or he has felt or acted this way in the past two weeks.

If a sentence was true about your child most of the time, check TRUE.

If it was only sometimes true, check SOMETIMES.

If a sentence was not true about your child, check NOT TRUE.

		NOT TRUE	SOMETIMES	TRUE
1.	S/he felt miserable or unhappy			ū
2.	S/he didn't enjoy anything at all		ū	
3.	S/he felt so tired that s/he just sat around and did nothing		ū	
4.	S/he was very restless		ū	ū
5.	S/he felt s/he was no good any more			ū
6.	S/he cried a lot		ū	ū
7.	S/he found it hard to think properly or concentrate		ū	ū
8.	S/he hated him/herself		ū	ū
9.	S/he felt s/he was a bad person			ū
10.	S/he felt lonely		ū	ū
11.	S/he thought nobody really loved him/her		ū	ū
12.	S/he thought s/he could never be as good as other kids		ū	ū
13.	S/he felt s/he did everything wrong		ū	٦

Copyright Adrian Angold & Elizabeth J. Costerllo, 1987; Developed Epidemiology Program, Duke University Reproduced with permission from developer, may be reproduced for use with one's own patients.

#### **SMFQ Scoring**

(Short Mood and Feelings Questionnaire)

# Scoring the SMFQ

Note: the SMFQ has been validated for use in children age 6 years and up.

The SMFQ should not be used to make a definitive diagnosis of depression. It has usefulness as a screening tool for situations where depression is suspected, and as an aid toward following a child's symptom severity and treatment response over time.

#### Scoring:

Assign a numerical value to each answer as follows:

Not true = 0

Sometimes = 1

True = 2

Add up the assigned values for all 13 questions. Record the total score.

A total score on the child version of the SMFQ of 8 or more is considered significant.

Sensitivity of 60% and specificity of 85% for major depression at a cut off score of 8 or higher. Source is Angold A, Costello EJ, Messer SC. "Development of a short questionnaire for use in epidemiological studies of depression in children and adolescents." *International Journal of Methods in Psychiatric Research* (1995), 5:237-249.

Sensitivity/specificity statistics of the parent version is not reported in the literature. If your patient does not complete the child version of SMFQ, repeated administration of the parent version over time should still be useful for symptom tracking.

# Tool Kit Survey

To help us continuously improve our tool kits, education, and communication with providers, please take this short survey regarding the Behavioral Health Toolkit by scanning the QR code with your mobile devise or visiting https://forms.office.com/r/m6XCEWq9hY



Thank you so much for your feedback!

# References

References:

- 1. APA Center for Psychology and Health Briefing Series on the Role of Psychology in Health Care Primary Care. (2014) <u>https://www.apa.org/health/briefs/primary-care.pdf</u>
- 2. Hunter, C. L., Goodie, J. L., Oordt, M. S., & Dobmeyer, A. C. (2009). Integrated behavioral health in primary care: Step-by-step guidance for assessment and intervention. Washington, DC: American Psychological Association.
- Handy, A., Mangal, R., Stead, T. S., Coffee, R. L., Jr, & Ganti, L. (2022). Prevalence and Impact of Diagnosed and Undiagnosed Depression in the United States. Cureus, 14(8), e28011. <u>https://doi.org/10.7759/cureus.28011</u>
- Ma, Y., Xiang, Q., Yan, C. *et al.* Relationship between chronic diseases and depression: the mediating effect of pain. *BMC Psychiatry* 21, 436 (2021). <u>https://doi.org/10.1186/s12888-021-03428-3</u>
- 5. Park, M., & Unützer, J. (2011). Geriatric depression in primary care. *The Psychiatric clinics of North America*, *34*(2), 469–x. <u>https://doi.org/10.1016/j.psc.2011.02.009</u>
- 6. American Psychiatric Association. Anxiety Disorders. In: *Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Text Revision*. American Psychiatric Association; 2022: pp. 215-231.
- Obuobi-Donkor, G., Nkire, N., & Agyapong, V. I. O. (2021). Prevalence of Major Depressive Disorder and Correlates of Thoughts of Death, Suicidal Behaviour, and Death by Suicide in the Geriatric Population-A General Review of Literature. *Behavioral sciences (Basel, Switzerland)*, 11(11), 142. <u>https://doi.org/10.3390/bs11110142</u>
- Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2005 Jun;62(6):617-27. <u>PMID: 15939839</u>
- US Preventive Services Task Force; Mangione CM, Barry MJ, Nicholson WK, Cabana M, Chelmow D, Coker TR, Davidson KW, Davis EM, Donahue KE, Jaén CR, Kubik M, Li L, Ogedegbe G, Pbert L, Ruiz JM, Silverstein M, Stevermer J, Wong JB. Screening for Depression and Suicide Risk in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2022 Oct 18;328(15):1534-1542. doi: 10.1001/jama.2022.16946. PMID: 36219440.
- 10.Bains, N. and Abdijadid, S. (2023), *Major Depressive Disorder*, NIH: National Library of Medicine. <u>https://www.ncbi.nlm.nih.gov/books/NBK559078/</u>
- 11. American Academy of Professional Coders. (2017). *Coding for Major Depressive Disorder*. <u>https://www.hamiltonhealth.com/wp-content/uploads/2017/08/AAPC\_Depressive-Disorder-ICD-10-BH\_Ref\_Guide.pdf</u>